ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

garsorasib

Also written as “D-1553”, “IN10018 in combination with D-1553” and “D-1553 Tablet”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Drug pageGarsorasib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 27, 20208 company-led studies, 4 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InventisBio62 open or runningphase 2since Sep 27, 2020Sep 27, 2020Dec 31, 2027phase 2 · NCT05379946
InxMed (Shanghai)its history only11 open or runningphase 3since Aug 29, 2025Aug 29, 2025Sep 2028phase 3 · NCT07174908
Sino Biopharmaceuticalits history only11 open or runningphase 3since Mar 3, 2024Mar 3, 2024none ahead

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of InventisBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2020First study: phase 2 study in Solid Tumor, AdultFirst studyNCT04585035 · 180 enrolled · United States, Australia, Korea, Republic of and more
  2. Jan 25, 2022Named garsorasibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, D-1553
  3. May 13, 20222 phase 2 studiesNCT05383898, NCT05379946
  4. Aug 5, 2022Phase 2 study in NSCLCNCT05492045 · 22 enrolled · China
  5. Oct 17, 2023Phase 1 study in Healthy MaleNCT06105255 · 45 enrolled · China
  6. Nov 27, 2023Phase 1 study in Mass Balance StudyNCT06233916 · 8 enrolled · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Solid TumorNCT05379946

TargetBeta

KRAS →read by rule
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 6 InventisBio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06233916Mass Balance Study · China1CompletedJan 3, 20248
NCT06105255Healthy Male · China1CompletedFeb 2, 202445
NCT05492045NSCLC · China2TerminatedJun 14, 202422
NCT05383898NSCLC · China2CompletedNov 17, 2023225
NCT05379946Solid Tumor · China2Active, not recruitingDec 31, 202792
NCT04585035Solid Tumor, Adult · United States, Australia, Korea, Republic of and more2Active, not recruitingApr 30, 2024180

How it is read

Names in the registry

  • “D-1553”, 5 entries
  • “IN10018 in combination with D-1553”, 1 entry
  • “D-1553 Tablet”, 1 entry
  • “[14C] D-1553”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.